Louis Breton, Rampart Bioscience CEO
October 24, 2023 07:00 AM EDT
Financing
Startups
Cell/Gene Tx

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Ryan Cross

Senior Science Correspondent

A new Cal­i­for­nia biotech start­up has launched with plans to de­vel­op ge­net­ic med­i­cines that are durable, re­doseable, and per­haps most im­por­tant­ly, don’t over­whelm health bud­gets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times